June 18, 2024

Eli Lilly (LLY) has two blockbuster drugs Mounjaro and Zepbound boosting sales. Meanwhile, the company couldn’t make enough .

April 21, 2024

Eli Lilly (LLY) can’t keep up with demand for Mounjaro, and now it has to make Zepbound too. That’s good news for shareholders.

January 7, 2024

Eli Lilly (LLY) could be a leading stock for 2024 as its diabetes drug Mounjaro and its weight loss drug Zepbound are now available.

August 29, 2023

Eli Lilly (LLY) stock jumped following earnings which saw its diabetes drug Monjaro sales soar and news it could reduce heart risk.

June 12, 2023

Eli Lilly (LLY) shares have been soaring as Mounjaro for weight loss and Donanemab for Alzeimer’s could fuel profits for years.

March 7, 2023

Eli Lilly (LLY) capped the price of insulin it provides to Americans at $35 a month. But LLY’s weight loss drug should be the big news.

December 1, 2022

Eli Lilly (LLY) continues to rise as it has developed what could become the next big weight loss drug, pending approval from the FDA.

September 28, 2022

Eli Lilly (LLY) has two potential blockbuster drugs — for weight loss and Alzheimer’s — that could bring big profits down the road.

September 17, 2024

Eli Lilly (LLY) is expected to report qtrly profits (EPS) and revenues:

Profits Estimates: $4.48 vs. $2.17 = +106%
Revenue Est: +29%